Immunotherapy has greatly improved our ability to treat cancer by tapping into the immune system, especially its powerful T cells. These T cells can be utilized therapeutically in multiple ways. Several current immunotherapies involve taking T cells from both patients’ blood and their tumors, which enables doctors to supply patients with powerful tumor-targeting forces that can potentially help eliminate their disease.
In this webinar for patients and caregivers, Philip Greenberg, M.D., member and head of the Program in Immunology at the Fred Hutchinson Cancer Research Center and professor of medicine and immunotherapy at the University of Washington in Seattle, and one of the pioneers of this cell-based immunotherapy approach (known as adoptive cell therapy), discusses how these cutting-edge strategies are currently being used in the clinic as well as how they might be improved moving forward.
This webinar was recorded June 26, 2018, and published July 10, 2018.
The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is made possible with generous support from Bristol-Myers Squibb, with additional support from Regeneron, Sanofi Genzyme, and Adaptimmune.
